## A BILL FOR AN ACT

RELATING TO HEALTH.

## BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

- 1 SECTION 1. The legislature finds that many patients who
- 2 have been diagnosed with sexually transmitted diseases,
- 3 including chlamydia and gonorrhea, have sexual partners who
- 4 refuse to seek treatment. To prevent reinfection, adequate
- 5 treatment of sexually transmitted diseases should include
- 6 treatment of sexual partners. Expedited partner therapy is a
- 7 partner treatment approach where partners of patients who test
- 8 positive for certain sexually transmitted diseases are provided
- 9 medication without previous medical evaluation.
- 10 The legislature further finds that because of expedited
- 11 partner therapy's effectiveness in reducing reinfection rates,
- 12 the Centers for Disease Control and Prevention has recommended
- 13 its use since 2006 among heterosexual partners of patients
- 14 diagnosed with chlamydia or gonorrhea when it is unlikely the
- 15 partners will seek timely evaluation and treatment. The
- 16 legislature additionally finds that Hawaii has high reported
- 17 rates of chlamydia. The most recent Centers for Disease Control
- 18 and Prevention data ranks Hawaii twenty-second in the nation for



- 1 reported chlamydia infection rates, with the disease peaking in
- 2 the age group between fifteen and twenty-four years.
- 3 The legislature also finds that primary care providers,
- 4 including persons licensed under chapter 453, Hawaii Revised
- 5 Statutes, and advanced practice registered nurses with
- 6 prescriptive authority under chapter 457, Hawaii Revised
- 7 Statutes, currently diagnose and treat persons with sexually
- 8 transmitted diseases. Expedited partner therapy will permit
- 9 these health professionals to adequately treat sexually
- 10 transmitted diseases and prevent reinfection through the
- 11 treatment of sexual partners.
- 12 The purpose of this Act is to allow health professionals to
- 13 provide expedited partner therapy, in accordance with Centers
- 14 for Disease Control and Prevention guidelines and
- 15 recommendations, to the heterosexual partners of a patient who
- 16 has been diagnosed as having chlamydia or gonorrhea.
- 17 SECTION 2. Chapter 453, Hawaii Revised Statutes, is
- 18 amended by adding a new part to be appropriately designated and
- 19 to read as follows:
- 20 "PART . EXPEDITED PARTNER THERAPY
- 21 §453-A Definitions. As used in this part:

1	"Expedited partner therapy" means the indirect treatment or					
2	heterosexual partners of a patient who has been diagnosed as					
3	having a sexually transmitted disease through the dispensing or					
4	prescribing of antibiotic therapy for the treatment of the					
5	heterosex	ual partners to the patient without the physical				
6	examinati	on of the heterosexual partners by a health				
7	professio	nal.				
8	"Hea	1th professional" means any of the following:				
9	(1)	A person licensed or otherwise authorized by law to				
10		practice medicine or surgery under this chapter and				
11		whose scope of practice includes the diagnosis and				
12		treatment of sexually transmitted diseases;				
13	(2)	An advanced practice registered nurse with				
14		prescriptive authority under chapter 457 and duly				
15		licensed in the State; or				
16	(3)	For the purpose of dispensing antibiotic therapy under				
17		this section, a pharmacist who is licensed or				
18		otherwise authorized to engage in the practice of				
19		pharmacy under chapter 461.				
20	"Sex	ual activity" means sexual intercourse, cunnilingus,				
21	fellatio,	anal intercourse, or any other intrusion, however				
22	slight, o	f any part of a person's body or of any object into the				

- 1 genital or anal openings of another person's body, but emission
- 2 of semen is not required.
- 3 "Sexually transmitted disease" means chlamydia or
- 4 gonorrhea, as recommended by the Centers for Disease Control and
- 5 Prevention for expedited partner therapy.
- 6 §453-B Expedited partner therapy. (a) A health
- 7 professional may, in addition to treating a patient, provide
- 8 expedited partner therapy to the partners of the patient if all
- 9 of the following requirements are met:
- 10 (1) The patient has a laboratory-confirmed or suspected
- 11 clinical diagnosis of a sexually transmitted disease;
- 12 (2) The patient indicates that the patient has partners
- with whom the patient has engaged in sexual activity
- 14 within the sixty-day period immediately preceding the
- diagnosis of a sexually transmitted disease; and
- 16 (3) The patient indicates that the patient's partners are
- 17 unable or unlikely to seek clinical services in a
- 18 timely manner.
- 19 (b) A health professional who provides expedited partner
- 20 therapy as authorized in this section shall do all of the
- 21 following:

1	.(1)	Dispense or prescribe antibiotic therapy in the name
2		of the partners, if known, without the physical
3		examination of the partners by the health
4		professional. Notwithstanding any law to the
5	·	contrary, if the name of the partners are not known,
6		the health professional shall dispense or prescribe
7		the antibiotic therapy in the name of "Expedited
8		Partner Therapy";
9	(2)	Convey to the patient that it is important to notify
10		the patient's partners of the patient's diagnosis and
11		that it is important for the partners to obtain
12		medical care for a complete evaluation, testing for
13		sexually transmitted diseases, counseling, and
14		treatment;
15	(3)	Distribute to the patient the information sheet
16		developed pursuant to section 453-C; and
17	(4)	Follow all Centers for Disease Control and Prevention
18		guidelines related to the practices and
19		recommendations for expedited partner therapy.
20	§ <b>4</b> 53	-C Information sheet. The department of health shall
21	develop a	nd, upon request, distribute to health professionals

1	subject t	o this part an information sheet that includes all of
2	the follo	wing:
3	(1)	A description of expedited partner therapy and its
4		purpose;
5	(2)	A notice that an individual who has been treated for a
6		sexually transmitted disease should be retested after
7		treatment to detect possible persistent or recurrent
8		infection, including information on the timing of
9		retesting, as recommended by the Centers for Disease
10		Control and Prevention;
11	(3)	A warning about the possible dangers of administering
12		antibiotic therapy to a pregnant individual;
13	(4)	Information about antibiotics dispensed or prescribed
14		and dosages of those antibiotics dispensed or
15		prescribed, as recommended by the Centers for Disease
16		Control and Prevention;
17	(5)	A warning about the risk of allergies to and drug
18		interactions with the antibiotics described in
19		<pre>paragraph (4);</pre>
20	(6)	Information about sexually transmitted diseases, the
21		treatment of sexually transmitted diseases, and the
22		prevention of sexually transmitted diseases;

1	(7)	A notice that the patient and the patient's partners
2		should abstain from sexual activity for seven days
3		after the patient and the partners have completed the
4		antibiotic therapy;
- 5	(8)	A notice that the partners should be tested for
6		sexually transmitted diseases;
7	(9)	A notice of the risk to the patient, the partners, and
8		others, including the public health, if a sexually
9		transmitted disease is not completely treated;
10	(10)	A notice of the responsibility of the patient to
11		notify sexual partners of the risk of sexually
12		transmitted diseases and the importance of examination
13		and treatment for sexually transmitted diseases; and
14	(11)	A statement advising any individual who has any
15		questions regarding anything in the information sheet
16		to contact a health professional or the department of
17		health.
18	§453	-D Limitation of liability. A health professional who
19	provides	expedited partner therapy as authorized under section
20	453-B, in	cluding a person licensed or otherwise authorized by
21	law to pr	actice medicine or surgery under this chapter, an
22	advanced ]	practice registered nurse with prescriptive authority
	CDASE UD1	TMC 2012_2772

- 1 under chapter 457, or a pharmacist who is licensed or otherwise
- 2 authorized to engage in the practice of pharmacy under chapter
- 3 461, shall not be subject to prosecution in a criminal
- 4 proceeding, liable for damages in a civil action, or subject to
- 5 disciplinary action under sections 453-8 and 453-8.2 for
- 6 personal injury, death, or other consequences arising from or
- 7 related in any way to the provision of expedited partner therapy
- 8 by the health professional; provided that this section shall not
- 9 apply if the action of the health professional in providing
- 10 expedited partner therapy constitutes gross negligence."
- 11 SECTION 3. Chapter 457, Hawaii Revised Statutes, is
- 12 amended by adding a new section to be appropriately designated
- 13 and to read as follows:
- 14 "§457- Advanced practice registered nurses; expedited
- 15 partner therapy. Advanced practice registered nurses who meet
- 16 the definition of a health professional as defined in section
- 17 453-A, shall be authorized to provide expedited partner therapy
- 18 in accordance with part of chapter 453."
- 19 SECTION 4. Section 328-16, Hawaii Revised Statutes, is
- 20 amended as follows:
- 21 1. By amending subsections (a), (b), and (c) to read:

1	"(a)	A prescription drug shall be dispensed only if its
2	label bear	rs the following:
3	(1)	The name, business address, and telephone number of
4		the seller. The business address shall be the
5		physical location of the pharmacy or the dispensing
6		practitioner's office;
7	(2)	[The] Except as otherwise authorized for expedited
8		partner therapy in section 453-B, the name of the
9		person for whom the drug was prescribed or the name of
10		the owner of the animal for which the drug was
11		prescribed;
12	(3)	The serial number of the prescription;
13	(4)	The date the prescription was prepared;
14	(5)	The name of the practitioner if the seller is not the
15		practitioner;
16	(6)	The name, strength, and quantity of the drug;
17	(7)	The "use by" date for the drug, which shall be:
18		(A) The expiration date on the manufacturer's
19		container; or
20		(B) One year from the date the drug is dispensed,
21		whichever is earlier;
22	(8)	The number of refills available, if any;
	SB655 HD1	HMS 2013-2772

21

22

1	(9)	In the case of the dispensing of an equivalent generic
2		drug product, the statement "same as (brand name of
3		the drug product prescribed or the referenced listed
4		drug name) ", or words of similar meaning; and
5	(10)	Specific directions for the drug's use; provided that
6		if the specific directions for use are too lengthy for
7		inclusion on the label, the notation "take according
8		to written instructions" may be used if separate
. 9		written instructions for use are actually issued with
10		the drug by the practitioner or the pharmacist, but in
11		no event shall the notation "take as directed",
12		referring to oral instructions, be considered
13		acceptable.
14	If any pr	escription for a drug does not indicate the number of
15	times it	may be refilled, if any, the pharmacist shall not
16	refill th	at prescription unless subsequently authorized to do so
17	by the pr	actitioner. The act of dispensing a prescription drug
18	other tha	n a professional sample or medical oxygen contrary to
19	this subs	ection shall be deemed to be an act that results in a
20	drug bein	g misbranded while held for sale.

subsection (a), a prescription drug shall be dispensed only:

SB655 HD1 HMS 2013-2772

(b) In addition to the requirements enumerated in

_	( ± /	by a busingerse baradane to a varia brescriberou [of-1]
2		section 461-1[+], or section 453-B;
3	(2)	By a medical oxygen distributor pursuant to a
4		prescription or certificate of medical necessity;
5		provided that the drug to be dispensed is medical
6		oxygen; or
7	(3)	By a practitioner to an ultimate user; provided that:
8		(A) [The] Except as otherwise authorized for
9		expedited partner therapy in section 453-B, the
10		practitioner shall inform the patient, prior to
11		dispensing any drug other than a professional
12		sample, that the patient may have a written,
13		orally ordered, or electronically transmitted or
14		conveyed prescription directed to a pharmacy or a
15		medical oxygen distributor of the patient's own
16		choice;
<b>17</b>		(B) The practitioner shall promptly record in the
18		practitioner's records:
19		(i) The prescription in full;
20		(ii) The name, strength, and quantity of the
21		drug, and specific directions for the drug's
22		use;

1	(iii)	The date the drug was dispensed; [and]
2	(iv)	[The] Except as otherwise authorized for
3		expedited partner therapy in section 453-B,
4		the name and address of the person for whom
5		the drug was prescribed or the name of the
6		owner of the animal for which the drug was
7		prescribed; and
8	<u>(v)</u>	Prescription drugs dispensed or prescribed
9		for expedited partner therapy as authorized
10		under section 453-B.
11	(C) The	records described in subparagraph (B) shall
12	be s	ubject to the inspection of the department or
13	its	agents at all times; and
14	(D) No u	ndisclosed rebate, refund, commission,
15	pref	erence, discount, or other consideration,
16	whet	her in the form of money or otherwise, has
17	been	offered to the practitioner as compensation
18	or i	nducement to dispense or prescribe any
19	spec	ific drug in preference to other drugs that
20	migh	t be used for the identical therapeutic
21	indi	cation.

1	(C)	A pr	escri	ption may be communicated in writing, orally,
2	or by ele	ectron	ic tr	ansmission, and shall include the following
3	informati	.on:		
4	(1)	The	autho	rization of the practitioner noted as
5		foll	ows:	
6		(A)	Writ	ten prescriptions shall include the original
7		-	sign	ature of the practitioner;
8		(B)	Oral	prescriptions shall be promptly recorded by
9			the	pharmacist or medical oxygen distributor and
10			shal	l include the practitioner's oral code
11			desi	gnation; and
12		(C)	Elec	tronic prescriptions shall be irrefutably
13	•		trac	eable to the prescribing practitioner by a
14			reco	gnizable and unique practitioner identifier
15			such	as:
16			(i)	A bitmap or graphic image of the
17				prescriber's handwritten signature and the
18				prescriber's oral code designation (or
19				license number or other identifier if the
20				<pre>prescriber is an out-of-state practitioner);</pre>
21			(ii)	An electronic signature;
22		(:	iii)	A digital signature; or

1		(iv) By other means as approved by the director;
2	(2)	The date of issuance;
3	(3)	The practitioner's name, business telephone number,
4		and business address, unless the practitioner is
5		otherwise uniquely identified and the pharmacy or
6		medical oxygen distributor dispensing the prescription
7		has the prescriber's contact information on file
8		accessible within the dispensing area;
9	(4)	The name, strength, and quantity of the drug to be
10		dispensed, and specific directions for the drug's use;
11	(5)	[The] Except as otherwise authorized for expedited
12		partner therapy in section 453-B, the name and address
13		of the person for whom the prescription was written or
14		the name of the owner of the animal for which the drug
15		was prescribed, unless the pharmacy or medical oxygen
16		distributor dispensing the prescription has the
17		address on file accessible within the dispensing area;
18	(6)	The room number and route of administration, if the
19		patient is in an institutional facility; and
20	(7)	The number of allowable refills, if the prescription
21		is refillable. If the number of refills authorized by
22		the practitioner is indicated using the terms "as

I	neea	ed" or "prn", the prescription may be refilled up			
2	to t	to twelve months from the date the original			
3	pres	prescription was written. After the twelve-month			
4	peri	period, the "as needed" or "prn" prescription may be			
5	refi	lled for a subsequent three-month period;			
6	prov	ided:			
7	(A)	The prescription is refilled only once during the			
8		three-month period;			
9	(B)	The refill does not exceed a thirty-day supply of			
10		the drug;			
11	(C)	The refill does not provide any amount of the			
12		drug fifteen months beyond the date the original			
13		prescription was written;			
14	(D)	In the case of medical oxygen, the duration of			
15		therapy indicated on a certificate of medical			
16		necessity shall supersede any limitations or			
17		restrictions on refilling; and			
18	(E)	Subparagraphs (A) to (D) shall apply only to			
19		pharmacies and medical oxygen distributors			
20		practicing in the State."			
21	2. By am	ending subsection (g) to read:			

- 1 "(g) Any drug other than medical oxygen dispensed pursuant
- 2 to a prescription shall be exempt from the requirements of
- 3 section 328-15 (except paragraphs (1), (9), (11), and (12), and
- 4 the packaging requirements of paragraphs (7) and (8)), if the
- 5 drug bears a label containing:
- **6** (1) The name and address of the pharmacy;
- 7 (2) The serial number and the date of the prescription or
- **9** (3) The name of the practitioner;
- 10 (4) [The] Except as otherwise authorized for expedited
- 11 partner therapy in section 453-B, the name of the
- 12 patient;
- 13 (5) The directions for use; and
- 14 (6) Any cautionary statements contained in the
- 15 prescription.
- 16 This exemption shall not apply to any drug dispensed in the
- 17 course of the conduct of a business of dispensing drugs pursuant
- 18 to diagnosis by mail, or to a drug dispensed in violation of
- 19 subsection (a), (b), (c), or (d)."
- 20 SECTION 5. Section 328-17.6, Hawaii Revised Statutes, is
- 21 amended as follows:
- 22 1. By amending subsections (c) and (d) to read:

1	" (C)	Any pharmacist or medical oxygen distributor who
2	fills or	refills a prescription from an out-of-state
3	practitio:	ner shall:
4	(1)	Note the following on the prescription record: the
5		out-of-state practitioner's full name, address, and
6		telephone number;
7	(2)	Be responsible for validating and verifying the
8		practitioner's prescriptive authority by virtue of a
9		valid out-of-state license, a Drug Enforcement
10		Administration registration number, or other measures
11		as appropriate; and
12	(3)	[Demand] Except as otherwise authorized for expedited
13		partner therapy in section 453-B, demand proper
14		identification from the person whose name appears on
15		the prescription prior to filling the prescription, in
16		addition to complying with any identification
17		procedures established by the department for filling
18		and refilling an out-of-state prescription.
19	(d)	Before refilling a transferred out-of-state
20	prescript	ion, a pharmacist or medical oxygen distributor shall:
21	(1)	[Advise] Except as otherwise authorized for expedited
22		partner therapy in section 453-B, advise the person

1		whos	e name appears on the prescription that the
2		pres	cription on file at the originating out-of-state
3		phar	macy or medical oxygen distributor may be
4		canc	eled; and
5	(2)	Record all information required to be on a	
6		prescription, including:	
7		(A)	The date of issuance of the original
8			prescription;
9		(B)	The number of refills authorized on the original
10			prescription;
11		(C)	The date the original prescription was dispensed;
12		(D)	The number of valid refills remaining and the
13			date of the last refill;
14		(E)	The out-of-state pharmacy's or out-of-state
15			medical oxygen distributor's name, telephone
16			number, and address, and the original
17			prescription number or control number from which
18			the prescription information was transferred; and
19		(F)	The name of the transferor pharmacist or the
20			medical oxygen distributor's agent."
21	2.	By am	ending subsection (f) to read:

```
1
         "(f) An out-of-state prescription record shall state the
    date of filling or refilling and, except as otherwise authorized
2
3
    for expedited partner therapy in section 453-B, the local
4
    address of the person whose name appears on the prescription."
5
         SECTION 6. Section 328-17.7, Hawaii Revised Statutes, is
    amended by amending subsection (a) to read as follows:
6
7
               Every practitioner, pharmacist, or medical oxygen
8
    distributor who compounds, sells, or delivers any prescribed
9
    drug to a patient or a patient's agent shall maintain records
10
    that identify:
11
              The specific drug product dispensed, including:
         (1)
12
              (A)
                   The product's national drug code (NDC) number; or
13
              (B)
                   The brand name or the established name and the
14
                   name or commonly accepted abbreviation of the
15
                   principal labeler of the drug product dispensed,
16
                   the product strength, and the dosage form;
17
         (2)
              The quantity of the drug;
              Directions for use;
18
         (3)
19
         (4)
              The number of allowable refills;
20
              The date of initial dispensing and the dates of all
         (5)
21
              refilling;
22
              The date of any transfer of the prescription;
```

1	(7)	The name, business address, and telephone number of			
2		the recipient pharmacist or medical oxygen distributor			
3		for any transfer of prescription;			
4	(8)	The prescribing practitioner, including name, business			
5		address, and telephone number;			
6	(9)	The format (oral, written, or electronic) in which the			
7		prescription was received;			
8	(10)	[The] Except as otherwise authorized for expedited			
9		partner therapy in section 453-B, the patient,			
10		including name, address, and telephone number;			
11	(11)	The date of prescribing; and			
12	(12)	The name of the practitioner, pharmacist, or medical			
13		oxygen distributor dispensing the drug.			
14	Every pre	scription dispensed shall have the name of the			
15	pharmacist, dispensing practitioner, or medical oxygen				
16	distributor responsible for the dispensing appended to the				
17	prescription record, and every prescription record shall be				
18	preserved and legible for a period of not less than five years.				
19	The prescription records shall be subject at all times to the				
20	inspection of the director of health or the director's agent."				
21	SECT	ION 7. In codifying the new sections added by section			
22	2 of this	Act, the revisor of statutes shall substitute			
	SB655 HD1	HMS 2013-2772			

SB035 NDI HMS ZU13-Z/7Z

- 1 appropriate section numbers for the letters used in designating
- 2 the new sections in this Act.
- 3 SECTION 8. Statutory material to be repealed is bracketed
- 4 and stricken. New statutory material is underscored.
- 5 SECTION 9. This Act shall take effect July 1, 2050.

## Report Title:

Sexually Transmitted Diseases; Expedited Partner Therapy; Health Professionals; Prescription Drugs; Labeling; Record Keeping

## Description:

Allows health professionals, subject to certain requirements, to treat the heterosexual partners of patients diagnosed as having chlamydia or gonorrhea, the sexually transmitted diseases recommended by the Centers for Disease Control and Prevention for expedited partner therapy, by dispensing or prescribing medication to the heterosexual partners without examining the partners. Provides protection from criminal liability, legal liability, and disciplinary action for health professionals who provide expedited partner therapy as authorized. Requires the department of health to develop an information sheet about sexually transmitted diseases for use by health professionals who provide expedited partner therapy. Creates exceptions to prescription drug labeling and reporting requirements for expedited partner therapy. Effective July 1, 2050. (SB655 HD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.